For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Placebo | placebo controlled arm Placebo: Normal Saline | 0 | None | 1 | 32 | 0 | 32 | View |
| Very Low Dose Ketamine | 0.25 mg/kg of sub-dissociative ketamine as an experimental arm Ketamine: sub-dissociative ketamine | 0 | None | 14 | 35 | 0 | 35 | View |
| Low Dose Ketamine | 0.50 mg/kg of sub-dissociative ketamine as an experimental arm Ketamine: sub-dissociative ketamine | 0 | None | 12 | 30 | 0 | 30 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Hallucinations | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Anxiety | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Anxiety and Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Anxiety and Palpitations | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Dysphoria | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |